Michele Greco - Veru CFO Officer
| VERU Stock | USD 0.68 0.05 7.94% |
Insider
Michele Greco is CFO Officer of Veru Inc
| Age | 65 |
| Address | 2916 North Miami Avenue, Miami, FL, United States, 33127 |
| Phone | 305 509 6897 |
| Web | https://verupharma.com |
Michele Greco Latest Insider Activity
Tracking and analyzing the buying and selling activities of Michele Greco against Veru stock is an integral part of due diligence when investing in Veru. Michele Greco insider activity provides valuable insight into whether Veru is net buyers or sellers over its current business cycle. Note, Veru insiders must abide by specific rules, including filing SEC forms every time they buy or sell Veru'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Michele Greco over six months ago Acquisition by Michele Greco of 114903 shares of Veru at 1.92 subject to Rule 16b-3 |
Veru Management Efficiency
The company has return on total asset (ROA) of (0.6436) % which means that it has lost $0.6436 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.2672) %, meaning that it created substantial loss on money invested by shareholders. Veru's management efficiency ratios could be used to measure how well Veru manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to gain to -2.33 in 2024. Return On Capital Employed is likely to gain to -2.45 in 2024. At this time, Veru's Total Current Liabilities is comparatively stable compared to the past year. Non Current Liabilities Total is likely to gain to about 15.1 M in 2024, whereas Liabilities And Stockholders Equity is likely to drop slightly above 32.1 M in 2024.Similar Executives
| Showing other executives | INSIDER Age | ||
| Steven Shamah | 2Seventy Bio | N/A | |
| Kristin Ainsworth | Seres Therapeutics | N/A | |
| Reid McCarthy | Annovis Bio | 66 | |
| Biegie Lee | Novavax | N/A | |
| MBA MS | Anavex Life Sciences | 56 | |
| MS MD | 2Seventy Bio | N/A | |
| Mary Jenkins | Sarepta Therapeutics | N/A | |
| William III | 2Seventy Bio | 52 | |
| Louise RodinoKlapac | Sarepta Therapeutics | 46 | |
| Kathleen Wilkinson | 2Seventy Bio | 52 | |
| Mike Kelly | Lexicon Pharmaceuticals | N/A | |
| MBA III | Annovis Bio | 56 | |
| Michael Hoffman | Annovis Bio | 69 | |
| CPA CPA | Anavex Life Sciences | 41 | |
| Walter MD | Anavex Life Sciences | N/A | |
| Howard MBA | Iovance Biotherapeutics | 64 | |
| David MBA | Seres Therapeutics | 63 | |
| MD MPH | Anavex Life Sciences | N/A | |
| Jeffrey Ludwig | Puma Biotechnology | 58 | |
| Madan Jagasia | Iovance Biotherapeutics | N/A | |
| Ryan Brown | Sarepta Therapeutics | 46 | |
Management Performance
| Return On Equity | -1.27 | ||||
| Return On Asset | -0.64 |
Veru Inc Leadership Team
Elected by the shareholders, the Veru's board of directors comprises two types of representatives: Veru inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Veru. The board's role is to monitor Veru's management team and ensure that shareholders' interests are well served. Veru's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Veru's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Gary Barnette, Chief Officer | ||
| Gary Bird, Executive Affairs | ||
| Jason Davies, Europe, UK | ||
| Michele CPA, CFO Officer | ||
| Philip JD, Executive Counsel | ||
| FACS FACS, Pres Chairman | ||
| Martin Tayler, Executive Operations | ||
| MD MBA, Chief Officer | ||
| Samuel Fisch, Executive Communications | ||
| Domingo MD, Executive Operations | ||
| Michael JD, General VP | ||
| MD FACS, President Chairman | ||
| Michele Greco, CFO Officer | ||
| JD CPA, Executive Development | ||
| Joel Batten, Ex Franchise | ||
| Michael Purvis, General VP |
Veru Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Veru a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.27 | ||||
| Return On Asset | -0.64 | ||||
| Profit Margin | (2.65) % | ||||
| Operating Margin | (2.79) % | ||||
| Current Valuation | 83.34 M | ||||
| Shares Outstanding | 146.38 M | ||||
| Shares Owned By Insiders | 14.10 % | ||||
| Shares Owned By Institutions | 41.98 % | ||||
| Number Of Shares Shorted | 12.38 M | ||||
| Price To Earning | 240.00 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Veru Stock Analysis
When running Veru's price analysis, check to measure Veru's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Veru is operating at the current time. Most of Veru's value examination focuses on studying past and present price action to predict the probability of Veru's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Veru's price. Additionally, you may evaluate how the addition of Veru to your portfolios can decrease your overall portfolio volatility.